ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 3196 • 2016 ACR/ARHP Annual Meeting

    A Natural Language Processing System Can Capture Rheumatoid Arthritis Disease Activity Measures in US Veterans Across Multiple Sites

    Grant W. Cannon1, Shobhit Mehortra2, Brett South2, Ted R Mikuls3, Andreas M. Reimold4 and Brian C Sauer2, 1Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 2Salt Lake City VA and University of Utah, Salt Lake City, UT, 3Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, 4Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX

    Background/Purpose:    The retrieval of rheumatoid arthritis (RA) disease activity measures recorded in an electronic medical record through natural language processing (NLP) would significantly aid…
  • Abstract Number: 3197 • 2016 ACR/ARHP Annual Meeting

    Ultrasound Definitions for Cranial and Large Vessel Giant Cell Arteritis: Results of a Reliability Exercise on Images and Videos of the Omeract Ultrasound Large Vessel Vasculitis Task Force

    Stavros Chrysidis1, Christina Duftner2, Christian Dejaco3, Cristina Ponte4, Annamaria Iagnocco5, Bhaskar Dasgupta6, Maria Antonietta D'Agostino7, Eugenio De Miguel8, Ulrich Fredberg9, Wolfgang Hartung10, Alojzija Hocevar11, Tanaz A. Kermani12, Matthew J. Koster13, Tove Lorenzen14, Pierluigi Macchioni15, Marcin Milchert16, Naina Rastalsky17, Chetan Mukhtyar18, Valentin S. Schaefer19, Kenneth J. Warrington20, Lene Terslev21, George A. W. Bruyn22, Petra Hanova23, Uffe Møller Døhn24, Esperanza Naredo25, Carlo Alberto Scirè26, Greta Carrara27, Sofia Ramiro28, Andreas P Diamantopoulos29 and Wolfgang A. Schmidt19, 1Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, 2Medical University Innsbruck, Innsbruck, Austria, 3Rheumatology and Immunology, Medical University Graz, Graz, Austria, 4Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, 5Sapienza Università Di Roma,, Roma, Italy, 6Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 7Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, 8Hospital Universitario La Paz, Madrid, Spain, 9Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, 10Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, 11Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 12Rheumatology, University of California Los Angeles, Santa Monica, CA, 13Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, 14Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, 15Arcispedale Santa Maria Nuova, Reggio Emilia,, Reggio Emilia, Italy, 16Pomeranian Medical University, Szczecin,, Szczecin, Poland, 17St. Elizabeth's Medical Center, Boston, MA, Boston, MA, 18Norfolk and Norwich University Hospital, Norwich, United Kingdom, 19Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany, 20Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, 21Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, 22Rheumatology, MC Groep, Loenga, Netherlands, 23Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 24Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, 25Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain, 26Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, 27Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, 28Leiden University Medical Center, Leiden, Netherlands, 29Rheumatology, Haugesund Sanitetsforenings Revmatismesykehus, Haugesund, Norway

    Background/Purpose:   By a Delphi process, the OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal temporal arteries…
  • Abstract Number: 3198 • 2016 ACR/ARHP Annual Meeting

    Inter-Reader and Intra-Reader Reliability of the New Omeract Ultrasonographic Criteria for the Diagnosis of Calcium Pyrophosphate Deposition Disease

    Georgios Filippou1, Carlo Alberto Scirè2, Nemanja Damjanov3, Antonella Adinolfi4, Greta Carrara5, Valentina Picerno1, Carmela Toscano1, George A. W. Bruyn6, Maria Antonietta D'Agostino7, Andrea Delle Sedie8, Emilio Filippucci9, Marwin Gutierrez10, Mihaela Cosmina Micu11, Ingrid Moller12, Esperanza Naredo13, Pascal Zufferey14, Carlos Pineda15, francesco Porta16, Wolfgang A. Schmidt17, Lene Terslev18, Violeta Vlad19, Bruno Frediani1, Annamaria Iagnocco20 and OMERACT working group "US in CPPD", 1University of Siena, Siena, Italy, 2Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, 3Institute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia, 4Policlinico le Scotte, Siena, Italy, 5Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, 6Rheumatology, MC Groep, Loenga, Netherlands, 7University of Paris, Paris, France, 8Department Rheumatology, University of Pisa, Pisa, Italy, 9Clinica Reumatologica, Università Politecnica delle Marche, Jesi, Italy, 10Instituto Nacional de Rehabilitación, Mexico, Mexico, 11Division of Rheumatology, Department of Rehabilitation II, Clinical Rehabilitation Hospital, Cluj Napoca, Romania, 12Direction, Poal Institute of Rheumatology, Corbera de Llobregat, Spain, 13Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain, 14Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, 15Instituto Nacional de Rehabilitation, Mexico, Mexico, 16Hospital of Pistoia, Pistoia, Italy, 17Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany, 18Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, 19RCRD Research Center, Bucharest, Romania, 20Sapienza Università di Roma, Roma, Italy

    Background/Purpose: ultrasonography (US) has been implemented recently as a possible diagnostic method for CPPD[1]. However, data on the reliability of US in CPPD diagnosis are…
  • Abstract Number: 3199 • 2016 ACR/ARHP Annual Meeting

    Urate Crystal Deposition and Bone Erosion in Gout: Inside-out or Outside-in? a Dual Energy Computed Tomography Study

    Patapong Towiwat1, Anthony Doyle1, Gregory Gamble2, Paul Tan1, Opetaia Aati2, Anne Horne2, Lisa K. Stamp3 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, New Zealand

    Background/Purpose:  Imaging and pathology studies have shown that bone erosion is closely associated with monosodium urate (MSU) crystal deposition in tophaceous gout.  It is currently…
  • Abstract Number: 3200 • 2016 ACR/ARHP Annual Meeting

    Immunoscintigraphic Detection Of Tumor Necrosis Factor By Radiolabeled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis in Relation to Disease Activity: A Proof of Concept Study

    Ruth Wittoek1, Philippe Carron2, Bieke Lambert3, Paulien Meersseman1, Gust Verbruggen1, Filip van Den Bosch1 and Dirk Elewaut4, 1Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Department of Nuclear Medicine Ghent University Hospital, Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium, 4Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium

    Background/Purpose:   A recent randomized clinical trial in erosive osteoarthritis (OA) of finger joints with a TNF blocking agent, adalimumab, showed inhibition of radiographic progression…
  • Abstract Number: 3201 • 2016 ACR/ARHP Annual Meeting

    Diagnostic Value of Quantitative Sialoscintigraphy Compared to Labial Salivary Gland Biopsy in Patients with Suspected SjöGren’ Syndrome

    Maria Garcia-Gonzalez1, Maria Jesus Gonzalez-Soto2, Ivan Ferraz-Amaro1, Hiurma Sanchez1, Vanesa Hernandez1, Maria Angeles Gomez2 and Sagrario Bustabad1, 1Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, 2Nuclear Medicine, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain

    Background/Purpose: Salivary gland dysfunction is one of the most common features of Sjögren' syndrome (SS). Sialoscintigraphy (sSC) is the only technique nowadays available to objectify…
  • Abstract Number: 3202 • 2016 ACR/ARHP Annual Meeting

    Clinical and Ultrasonographic Evaluation of Joint Involvement in Patients with Systemic Sclerosis

    María Victoria Martire1, Priscila Marcaida2, Santiago Scarafia3, Gloria Crespo2, Anastasia Secco4, Lida Santiago2 and Marta Mamani2, 1Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 2Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, 3Hospital Bernardino Rivadavia, CABA, Argentina, 4Hospital Bernardino Rivadavia, Buenos Aires, Argentina

    Background/Purpose: Systemic sclerosis is a multisystem disease characterized by the development of microangiopathy and subsequent fibrosis of skin and internal organs. The joint involvement is…
  • Abstract Number: 3203 • 2016 ACR/ARHP Annual Meeting

    Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort

    Claire Deakin1, Raquel Campanilho-Marques2, Stefania Simou3, Elena Moraitis4, Eleanor Pullenayegum5,6, Lucy R Wedderburn4,7,8, Clarissa Pilkington9 and Juvenile Dermatomyositis Research Group (JDRG), 1Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, 2Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, 3Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, 4Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, 5Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, 6Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 7Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 8Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 9Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

    Background/Purpose:  Cyclophosphamide (CYC) has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the efficacy of…
  • Abstract Number: 3204 • 2016 ACR/ARHP Annual Meeting

    Body Composition and Adipose Tissue Distribution in Juvenile Dermatomyositis and Associations with Cardiac Function

    Birgit Nomeland Witczak1, Kristin Godang2, Thomas Schwartz3, Nicoleta Cristina Olarescu4, Berit Flatø5,6, Jens Bollerslev5,7, Ivar Sjaastad5,8,9 and Helga Sanner5,6, 1Oslo University Hospital, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 2Department of Specialised Endocrinology, Oslo University Hospital, Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 3Department of Infectious Diseases, Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 4Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 5Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, 6Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 7Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 8Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 9Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Lipodystrophy and metabolic abnormalities occur frequently in juvenile dermatomyositis (JDM) and redistribution of adipose tissue has been reported in several rheumatic diseases. Visceral adipose…
  • Abstract Number: 3205 • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial

    Fabrizio De Benedetti1, Jordi Anton2, Eldad Ben-Chetrit3, Inmaculada Calvo4, Joost Frenkel5, Marco Gattorno6, Hal M. Hoffman7, Ozgur Kasapcopur8, Isabelle Koné-Paut9, Helen Lachmann10, Michel Moutschen11, Seza Ozen12, Pierre Quartier13, Anna Simon14, Andrew Zeft15, Karine Lheritier16, Antonio Speziale16 and Guido Junge16, 1IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, 2Hospital Sant Joan de Déu, Barcelona, Spain, 3Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, 4Hospital Universitario y Piltecnico La Fe, Valencia, Spain, 5University Medical Center Utrecht, Utrecht, Netherlands, 6Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, 7University of California at San Diego, San Diego, CA, 8Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, 9Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, 10UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, 11C.H.U. Sart-Tilman, Liege, Belgium, 12Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, 13Hôpital Necker-Enfants Malades, Paris, France, 14General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 15Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, 16Novartis Pharma AG, Basel, Switzerland

    Background/Purpose:  Periodic fever syndromes (PFS) are rare auto-inflammatory conditions that include, among others, cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…
  • Abstract Number: 3206 • 2016 ACR/ARHP Annual Meeting

    Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study

    Paul Brogan1, Michaël Hofer2, Jasmin B. Kuemmerle-Deschner3, Bernard Lauwerys4, Antonio Speziale5, Xiaoling Wei6 and Ronald Laxer7, 1Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, 2Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 3University Hospital Tuebingen, Tuebingen, Germany, 4Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, 5Novartis Pharma AG, Basel, Switzerland, 6Shanghai Novartis Trading Limited, Shanghai, China, 7Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose:  Canakinumab (CAN) has been shown not to impair antibody production following vaccination in children in an open-label phase 3 study (NCT01302860).1 Here we present…
  • Abstract Number: 3207 • 2016 ACR/ARHP Annual Meeting

    The Deficiency of Adenosine Deaminase Type 2 (DADA2)—Results of Anti-TNF Treatment in a Cohort of Patients with a History of Stroke

    Amanda K. Ombrello1, Karyl Barron2, Patrycja Hoffmann1, Camilo Toro3, Deborah L. Stone4, Gineth Pinto-Patarroyo4, Anne Jones4, Tina Romeo5, Ariane Soldatos6, Qing Zhou7, Natalie Deuitch5, Jing Qin2, Ivona Aksentijevich4 and Daniel L. Kastner4, 1Inflammatory Diseases Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 3NIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 4Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 5National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 6National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 7Inflammatory Disease Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

    Background/Purpose: The deficiency of adenosine deaminase type 2 (DADA2) is an autosomal recessive disease resulting from biallelic mutations in CECR1. Patients commonly present with vascular…
  • Abstract Number: 3208 • 2016 ACR/ARHP Annual Meeting

    Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”,“Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases

    Gina A. Montealegre Sanchez1, Adam Reinhardt2, Paul Brogan3, Dawn C. Chapelle4, Hanna Kim4, Samantha Judd4, Bahar Kost4, Michelle O'Brien4, Wendy Goodspeed5, Robert A. Colbert4, Meryl Waldman6, Deborah L. Stone7, Ling Gao8, JA Dare8, Susanne Schalm9, Thomas L. Klausmeier10, Sara Murias11, Yackov Berkun12, Diane Brown13, John D. Carter14, Fehime K Eroglu15, A. Zlotogorski16, Philip Hashkes17, Helmut Wittkowski18, Suzanne Ramsey19, Seza Ozen20, Adriana Almeida de Jesus21 and Raphaela Goldbach-Mansky22, 1NIAID/NIH, Bethesda, MD, 2Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, 3UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 4NIAMS/NIH, Bethesda, MD, 5Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, 6NIDDK/NIH, Bethesda, MD, 7NHGRI/NIH, Bethesda, MD, 8University of Arkansas for Medical Sciences, Little Rock, AR, 9LMU Munich, Munich, Germany, 10Riley Hospital for Children, Indianapolis, IN, 11Hospital Infantil La Paz, Madrid, Spain, 12Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 13Children's Hospital Los Angeles, Los Angeles, CA, 14Division of Rheumatology, University of South Florida, Tampa, FL, 15Department of Pediatrics, Hacettepe University Hospitals, Ankara, Turkey, 16Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 17Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, 18Pediatrics, University of Muenster, Muenster, Germany, 19Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, 20Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, 21National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, 22Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD

    Background/Purpose: Chronically elevated serum IP-10 (CXCL10) levels, and a prominent “interferon (IFN)-response gene signature” in patients with chronic neutrophilic dermatosis with lipodystrophy and elevated temperatures…
  • Abstract Number: 3209 • 2016 ACR/ARHP Annual Meeting

    Clinical and Radiological Outcomes of 5 Years Remission Steered Treatment in Early Rheumatoid and Undifferentiated Arthritis Patients

    Gülsah Akdemir1, L. Heimans2, R.J. Goekoop3, Maikel van Oosterhout4, J.B. Harbers5, C. Bijkerk6, G.M. Steup-Beekman7, L.R. Lard8, P.B.J. de Sonnaville9, B.A.M. Grillet10, TWJ Huizinga11 and Cornelia F. Allaart2, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Haga Hospital, The Hague, Netherlands, 4Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 5Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, 6Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 7Rheumatology, Bronovo Hospital, The Hague, Netherlands, 8Rheumatology, MCH Antoniushove Hospital, Leidschendam, Netherlands, 9Rheumatology, ADRZ, Goes, Netherlands, 10Rheumatology, Zorgsaam, Terneuzen, Netherlands, 11Leiden University Medical Centre, Leiden, Netherlands

    Background/Purpose: To assess clinical and radiological outcomes of induction therapy followed by 5 years disease activity score (DAS)-remission steered treatment in early arthritis patients. Methods:…
  • Abstract Number: 3210 • 2016 ACR/ARHP Annual Meeting

    10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes

    Merete Lund Hetland1, Kristian Stengaard-Pedersen2, Peter Junker1, Hanne Lindegaard1, Torkell Ellingsen1, Jan Pødenphant2, Henrik Skjødt1, Aage Vestergaard2, Bo Jannik Ejbjerg1, Søren Jacobsen1, Niels Steen Krogh1, Mikkel Ostergaard1 and Kim Hørslev-Petersen2, 1Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Glostrup, Denmark, 2Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark

    Background/Purpose:  Few RCTs have investigated long-term (10+ years) outcomes of goal-directed synovitis suppression in early rheumatoid arthritis (RA). The CIMESTRA trial was a 2-year double-blinded…
  • « Previous Page
  • 1
  • …
  • 1628
  • 1629
  • 1630
  • 1631
  • 1632
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology